Tempest Therapeutics, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-24. Between them they name 2 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Nicholas Rossettos, Chief Financial Officer, effective 2026-09-01
Effective September 1, 2026, the Board of Directors of the Company (the "Board") appointed Mr. Nicholas Rossettos as Chief Financial Officer Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary of the Company.
Appointed: Justin Trojanowski, Vice President, Finance, effective 2026-06-05
Effective June 5, 2026, the Board of Directors of the Company (the "Board") appointed Mr. Justin Trojanowski as Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company, in addition to his current role as Corporate Controller, Treasurer and Principal Accounting Officer of the Company.
Reported
On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
Reported
On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the "Company") of his or her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.
Tempest Therapeutics, Inc.'s funding history
Find people with the same kind of experience as the Chief Financial Officer at Tempest Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Tempest Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Tempest Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Tempest Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Tempest Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.